Shelton Capital Management’s Core Laboratories CLB Stock Holding History

Shelton Capital Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,476	Closed	-$205K	–	737
2022 Q1	$205K	Buy	+6,476	New	+$182K	0.01%	768
2021 Q3	–	Sell	-6,476	Closed	-$252K	–	816
2021 Q2	$252K	Buy	+6,476	New	+$232K	0.01%	667
2020 Q1	–	Sell	-5,964	Closed	-$225K	–	686
2019 Q4	$225K	Hold	5,964	–	–	0.01%	698
2019 Q3	$278K	Hold	5,964	–	–	0.02%	565
2019 Q2	$312K	Buy	5,964 +5,553	+1,351%	+$326K	0.02%	509
2019 Q1	$5.96K	Sell	411 -5,553	-93%	-$372K	0.02%	531
2018 Q4	$356K	Hold	5,964	–	–	0.02%	406
2018 Q3	$691K	Hold	5,964	–	–	0.04%	286
2018 Q2	$753K	Hold	5,964	–	–	0.05%	267
2018 Q1	$645K	Hold	5,964	–	–	0.04%	301
2017 Q4	$653K	Hold	5,964	–	–	0.04%	310
2017 Q3	$589K	Buy	5,964 +2,429	+69%	+$235K	0.04%	318
2017 Q2	$358K	Sell	3,535 -4,200	-54%	-$453K	0.03%	483
2017 Q1	$894K	Hold	7,735	–	–	0.06%	245
2016 Q4	$929K	Hold	7,735	–	–	0.07%	246
2016 Q3	$869K	Buy	+7,735	New	+$891K	0.07%	232

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shelton Capital Management's CLB Position: Q2 2022 in Review

Shelton Capital Management sold out of Core Laboratories (CLB) in Q2 2022, closing a stake of 6,476 shares — an estimated $205K sold.

Shelton Capital Management first reported a position in CLB in Q3 2016 and held it in 16 quarters. The position peaked at $929K in Q4 2016. 175 funds tracked by Wall St. Rank hold CLB as of Q2 2022.

Shelton Capital Management reported no remaining Core Laboratories position as of Q2 2022 after selling out during the quarter.
Shelton Capital Management sold 6,476 Core Laboratories shares in Q2 2022, an estimated $205K.
Shelton Capital Management first reported a position in Core Laboratories in Q3 2016 and held it in 16 quarters.
Shelton Capital Management's Core Laboratories position peaked at $929K in Q4 2016.
175 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2022.

Based on Shelton Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.